A former Par Pharma site in Irvine, CA, will now have a new tenant.

BioDuro-Sundia will acquire a 40,000-square-foot oral solid dose manufacturing site in Irvine, the company announced Monday.

The site will allow the company to scale up and cater to companies that need larger-scale production, Kent Payne, the president of development and manufacturing, said in a press release. The new site should be operational by the start of 2022. It will be able to produce 1 billion tablets and capsules a year, the company said.

Amy Abernethy now has a whole new set of tools to tap into as she scales up the clinical trial management platform at Verily.

The life sciences outfit — now officially a subsidiary of Alphabet on equal footing with Google — has acquired SignalPath for an undisclosed amount, giving it access to a system of digital solutions that make it easier to run clinical trials, and promise to simultaneously boost quality and efficiency.

BioVision has supplied Abcam with research tools since 1999, and now the two are making it official as part of a merger unveiled Monday.

Abcam will buyout BioVision as part of a $340 million acquisition deal to bring aboard the supplier’s biochemical and cell-based assays for biological research, as well as recombinant proteins, antibodies and enzymes.

The deal will give Abcam control of BioVision’s portfolio and allow for both the expansion of research existing areas of focus such as oncology, neuroscience and epigenetics and preparation to expand into new products. As a part of the deal, Abcam will develop and supply products and services to NKY, the previous owner of BioVision and receive support for ongoing development and commercialization of in vitro diagnostic products.

India is getting a manufacturing boost that will add the capacity to produce another 1 billion injectables.

Recipharm announced the construction of a new fill-finish facility in Uttarakhand, near Dehradun, in collaboration with the Sobti family. The development is the latest move in a partnership with the family, which began in 2019 after Recipharm invested in Nichepharm.

The site will up Recipharm’s sterile fill-finish service to complement already existing locations in France, Germany and Italy. The project’s next step is to gain authorization from European regulators.

For the second time in less than six months, Catalent will upgrade its sleek new facility in Anagni, Italy, this time to add biologics drug substance manufacturing capabilities to support an increase in demand.

Two new 2,000 liter single-use bioreactors with new manufacturing suites will support early-phase clinical development and late-stage commercial transfers, the company said in a press release, as well as space for another six bioreactors to be added in the future. The project is expected to add 100 new employees, and it should be operational in April 2023.